.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Cipla
Chinese Patent Office
Dow
Moodys
Healthtrust
Fish and Richardson
QuintilesIMS
AstraZeneca
Boehringer Ingelheim

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 040120

« Back to Dashboard

NDA 040120 describes PROCHLORPERAZINE MALEATE, which is a drug marketed by Duramed Pharms Barr, Ivax Sub Teva Pharms, Mylan, Sandoz, and Teva Pharms, and is included in eight NDAs. It is available from twenty suppliers. Additional details are available on the PROCHLORPERAZINE MALEATE profile page.

The generic ingredient in PROCHLORPERAZINE MALEATE is prochlorperazine maleate. There are twenty drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the prochlorperazine maleate profile page.

Summary for 040120

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Antiemetics
Antipsychotics
Formulation / Manufacturing:see details

Pharmacology for NDA: 040120

Ingredient-typePhenothiazines

Suppliers and Packaging for NDA: 040120

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PROCHLORPERAZINE MALEATE prochlorperazine maleate TABLET;ORAL 040120 ANDA Teva Pharmaceuticals USA, Inc. 0093-9643 0093-9643-01 100 TABLET, FILM COATED in 1 BOTTLE (0093-9643-01)
PROCHLORPERAZINE MALEATE prochlorperazine maleate TABLET;ORAL 040120 ANDA Teva Pharmaceuticals USA, Inc. 0093-9652 0093-9652-01 100 TABLET, FILM COATED in 1 BOTTLE (0093-9652-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE
Approval Date:Jul 11, 1996TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Jul 11, 1996TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
US Department of Justice
Novartis
Colorcon
Medtronic
Accenture
Julphar
Johnson and Johnson
UBS
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot